These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 32837984)

  • 1. Pandemic COVID-19: Current status and challenges of antiviral therapies.
    Chan W; He B; Wang X; He ML
    Genes Dis; 2020 Dec; 7(4):502-519. PubMed ID: 32837984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
    Uzunova K; Filipova E; Pavlova V; Vekov T
    Biomed Pharmacother; 2020 Nov; 131():110668. PubMed ID: 32861965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chloroquine and Hydroxychloroquine for the Prevention and Treatment of COVID-19: A Fiction, Hope or Hype? An Updated Review.
    Saghir SAM; AlGabri NA; Alagawany MM; Attia YA; Alyileili SR; Elnesr SS; Shafi ME; Al-Shargi OYA; Al-Balagi N; Alwajeeh AS; Alsalahi OSA; Patra AK; Khafaga AF; Negida A; Noreldin A; Al-Amarat W; Almaiman AA; El-Tarabily KA; Abd El-Hack ME
    Ther Clin Risk Manag; 2021; 17():371-387. PubMed ID: 33953559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological, molecular and pharmacological characteristics of chloroquine, hydroxychloroquine, convalescent plasma, and remdesivir for COVID-19 pandemic: A comparative analysis.
    Meo SA; Zaidi SZA; Shang T; Zhang JY; Al-Khlaiwi T; Bukhari IA; Akram J; Klonoff DC
    J King Saud Univ Sci; 2020 Oct; 32(7):3159-3166. PubMed ID: 32921965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 Pandemic - A Narrative Review of the Potential Roles of Chloroquine and Hydroxychloroquine.
    de Barros CM; Almeida CAF; Pereira B; Costa KCM; Pinheiro FA; Maia LDB; Trindade CM; Garcia RCT; Torres LH; Diwan S; Boralli VB
    Pain Physician; 2020 Aug; 23(4S):S351-S366. PubMed ID: 32942793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
    Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM;
    Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing against SAR-CoV-2 (COVID-19) pandemic.
    Tripathy S; Dassarma B; Roy S; Chabalala H; Matsabisa MG
    Int J Antimicrob Agents; 2020 Aug; 56(2):106028. PubMed ID: 32450198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates.
    Maisonnasse P; Guedj J; Contreras V; Behillil S; Solas C; Marlin R; Naninck T; Pizzorno A; Lemaitre J; Gonçalves A; Kahlaoui N; Terrier O; Fang RHT; Enouf V; Dereuddre-Bosquet N; Brisebarre A; Touret F; Chapon C; Hoen B; Lina B; Calatrava MR; van der Werf S; de Lamballerie X; Le Grand R
    Nature; 2020 Sep; 585(7826):584-587. PubMed ID: 32698191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial.
    González R; García-Otero L; Pons-Duran C; Marbán-Castro E; Goncé A; Llurba E; Gil MDM; Rodríguez-Zambrano MÁ; Chen H; Ramírez M; Bardají A; Menendez C
    Trials; 2020 Jul; 21(1):607. PubMed ID: 32616063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chloroquine and hydroxychloroquine in the treatment of COVID-19: the never-ending story.
    Gasmi A; Peana M; Noor S; Lysiuk R; Menzel A; Gasmi Benahmed A; Bjørklund G
    Appl Microbiol Biotechnol; 2021 Feb; 105(4):1333-1343. PubMed ID: 33515285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication
    Shytaj IL; Fares M; Gallucci L; Lucic B; Tolba MM; Zimmermann L; Adler JM; Xing N; Bushe J; Gruber AD; Ambiel I; Taha Ayoub A; Cortese M; Neufeldt CJ; Stolp B; Sobhy MH; Fathy M; Zhao M; Laketa V; Diaz RS; Sutton RE; Chlanda P; Boulant S; Bartenschlager R; Stanifer ML; Fackler OT; Trimpert J; Savarino A; Lusic M
    mBio; 2022 Apr; 13(2):e0370521. PubMed ID: 35229634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
    Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
    Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy.
    Drożdżal S; Rosik J; Lechowicz K; Machaj F; Kotfis K; Ghavami S; Łos MJ
    Drug Resist Updat; 2020 Dec; 53():100719. PubMed ID: 32717568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
    Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
    Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.
    Fantini J; Chahinian H; Yahi N
    Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32405156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of hydroxychloroquine/chloroquine against SARS-CoV-2 infection: A systematic review and meta-analysis.
    Kumar J; Jain S; Meena J; Yadav A
    J Infect Chemother; 2021 Jun; 27(6):882-889. PubMed ID: 33678548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19.
    Meo SA; Klonoff DC; Akram J
    Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4539-4547. PubMed ID: 32373993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Update on Antiviral Therapy Against SARS-CoV-2: How Far Have We Come?
    Indari O; Jakhmola S; Manivannan E; Jha HC
    Front Pharmacol; 2021; 12():632677. PubMed ID: 33762954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19).
    Shah S; Das S; Jain A; Misra DP; Negi VS
    Int J Rheum Dis; 2020 May; 23(5):613-619. PubMed ID: 32281213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.